CORCEPT THERAPEUTICS INC's ticker is CORT and the CUSIP is 218352102. A total of 289 filers reported holding CORCEPT THERAPEUTICS INC in Q1 2024. The put-call ratio across all filers is 1.61 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $2,503,225 | +56.5% | 77,046 | +21.4% | 0.06% | +53.7% |
Q1 2024 | $1,599,187 | +10.8% | 63,485 | +42.8% | 0.04% | +5.1% |
Q4 2023 | $1,443,671 | +21.0% | 44,448 | +1.5% | 0.04% | +14.7% |
Q3 2023 | $1,193,522 | +4516.2% | 43,807 | +3670.0% | 0.03% | +3300.0% |
Q2 2023 | $25,855 | +0.7% | 1,162 | -1.9% | 0.00% | 0.0% |
Q1 2023 | $25,667 | +4.2% | 1,185 | -2.3% | 0.00% | 0.0% |
Q4 2022 | $24,636 | -25.3% | 1,213 | -5.6% | 0.00% | 0.0% |
Q3 2022 | $33,000 | +22.2% | 1,285 | +14.3% | 0.00% | 0.0% |
Q2 2022 | $27,000 | +17.4% | 1,124 | +8.1% | 0.00% | – |
Q1 2022 | $23,000 | -95.9% | 1,040 | -96.3% | 0.00% | -100.0% |
Q4 2021 | $562,000 | +4.1% | 28,365 | +3.4% | 0.01% | -21.4% |
Q3 2021 | $540,000 | -34.1% | 27,438 | -26.4% | 0.01% | -46.2% |
Q2 2021 | $820,000 | +3.8% | 37,279 | +12.3% | 0.03% | -13.3% |
Q1 2021 | $790,000 | -23.7% | 33,190 | -16.2% | 0.03% | -37.5% |
Q4 2020 | $1,036,000 | +66.6% | 39,591 | +10.9% | 0.05% | +37.1% |
Q3 2020 | $622,000 | -1.6% | 35,715 | -5.0% | 0.04% | -66.7% |
Q2 2020 | $632,000 | – | 37,601 | – | 0.10% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
INGALLS & SNYDER LLC | 8,360,485 | $186,021 | 8.91% |
Novo Holdings A/S | 3,377,768 | $75,155,338 | 5.81% |
Parallel Advisors, LLC | 3,726,565 | $82,916,071 | 2.67% |
TANAKA CAPITAL MANAGEMENT INC | 35,539 | $791 | 2.14% |
S&T BANK/PA | 347,260 | $7,727 | 1.39% |
FAS Wealth Partners, Inc. | 310,771 | $6,914,655 | 0.88% |
Birchview Capital, LP | 50,000 | $1,112,500 | 0.83% |
Granite Investment Partners, LLC | 792,519 | $17,633,548 | 0.70% |
Bridge City Capital, LLC | 60,632 | $1,349,062 | 0.64% |
AJ WEALTH STRATEGIES, LLC | 509,934 | $11,346,032 | 0.55% |